Adoptive cell transfer (ACT) using chimeric antigen receptor (CAR)‐modified T cells can
induce durable remissions in patients with refractory B‐lymphoid cancers. By contrast …

Adoptive T cell transfer for cancer and chronic infection is an emerging field that shows
promise in recent trials. Synthetic-biology-based engineering of T lymphocytes to express …

The T cells of the immune system can target tumors and clear solid cancers following tumor-
infiltrating lymphocyte (TIL) therapy. We used combinatorial peptide libraries and a …

Human leucocyte antigen B* 27 (HLA-B* 27) is strongly associated with inflammatory
diseases of the spine and pelvis (for example, ankylosing spondylitis (AS)) and the eye (that …

Abstract Multiple SARS-CoV-2 Omicron sub-variants, such as BA. 2, BA. 2.12. 1, BA. 4, and
BA. 5, emerge one after another. BA. 5 has become the dominant strain worldwide …

KRAS mutations are broadly recognized as promising targets for tumor therapy. T cell
receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human …

T cell immunity can potentially eradicate malignant cells and lead to clinical remission in a
minority of patients with cancer. In the majority of these individuals, however, there is a …

Clonal selection theory proposed that individual T cells are specific for a single peptide–
MHC antigen. However, the repertoire of αβ T cell receptors (TCRs) is dwarfed by the vast …

The median overall survival for children with diffuse intrinsic pontine glioma (DIPG) is less
than one year. The majority of diffuse midline gliomas, including more than 70% of DIPGs …

The immunogenicity of malignant cells has recently been acknowledged as a critical
determinant of efficacy in cancer therapy. Thus, besides developing direct …